3.42
-0.05(-1.44%)
Currency In USD
| Previous Close | 3.29 |
| Open | 3.26 |
| Day High | 3.34 |
| Day Low | 3.2 |
| 52-Week High | 6.79 |
| 52-Week Low | 0.6 |
| Volume | 190,045 |
| Average Volume | 1.85M |
| Market Cap | 271.66M |
| PE | -6.51 |
| EPS | -0.51 |
| Moving Average 50 Days | 4.44 |
| Moving Average 200 Days | 2.39 |
| Change | 0.03 |
If you invested $1000 in I-Mab (IMAB) since IPO date, it would be worth $273.6 as of February 21, 2026 at a share price of $3.42. Whereas If you bought $1000 worth of I-Mab (IMAB) shares 5 years ago, it would be worth $61.29 as of February 21, 2026 at a share price of $3.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
GlobeNewswire Inc.
Oct 22, 2025 4:35 PM GMT
Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3WNo differe
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
GlobeNewswire Inc.
Oct 16, 2025 8:05 PM GMT
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong in
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global bio